• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.66% Nasdaq Down1.05%

    More On ALIOF



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    • Income Statement
    • Balance Sheet
    • Cash Flow

    Actelion Ltd. (ALIOF)

    -Other OTC
    136.36 Down 1.64(1.19%) 2:13PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Actelion Ltd.
    Gewerberstrasse 16
    Allschwil, 4123
    Switzerland - Map
    Phone: 41 61 565 65 65
    Fax: 41 61 565 65 00
    Website: http://www.actelion.com

    Index Membership:N/A
    Full Time Employees:2,495

    Business Summary 

    Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. It offers Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; and Opsumit, an orally available endothelin receptor antagonist for the treatment of PAH to delay disease progression. The company also provides Veletri, an intravenous prostacyclin for the treatment of PAH to enhance exercise capacity; and Ventavis, an inhaled synthetic analog of prostacyclin for the treatment of PAH to enhance a composite endpoint consisting of exercise tolerance, symptoms, and lack of deterioration. In addition, it offers Valchlor, a chemotherapeutic agent for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Europe, Japan, China, Russia, Mexico, and internationally. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Actelion Ltd.

    Key Executives 
    Mr. Jean-Paul Clozel M.D., 60
    Founder, Chief Exec. Officer and Director
    Ms. Martine Clozel , 60
    Founder, Chief Scientific Officer, Head of Drug Discovery Pharmacology & Preclinical Devel. and Sr. VP
    Mr. André C. Muller , 52
    Chief Financial Officer and Exec. Vice-Pres
    Mr. Otto Schwarz , 60
    Chief Operating Officer and Exec. VP
    Mr. Andrew C. Weiss ,
    Head of Investor Relations & Corp. Communications and Sr. VP
    Mr. Marian Borovsky , 46
    Sr. VP, Group Gen. Counsel and Corp. Sec.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.